| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536864 | Vaccine | 2017 | 7 Pages |
Abstract
HAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Katrin Bohm, Angela Filomena, Nicole Schneiderhan-Marra, Gérard Krause, Claudia Sievers,